Cite
Radiotherapy quality assurance for mesorectum treatment planning within the multi-center phase II STAR-TReC trial: Dutch results.
MLA
van den Ende, Roy P. J., et al. “Radiotherapy Quality Assurance for Mesorectum Treatment Planning within the Multi-Center Phase II STAR-TReC Trial: Dutch Results.” Radiation Oncology, vol. 15, no. 1, Feb. 2020, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s13014-020-01487-6.
APA
van den Ende, R. P. J., Peters, F. P., Harderwijk, E., Rütten, H., Bouwmans, L., Berbee, M., Canters, R. A. M., Stoian, G., Compagner, K., Rozema, T., de Smet, M., Intven, M. P. W., Tijssen, R. H. N., Theuws, J., van Haaren, P., van Triest, B., Eekhout, D., Marijnen, C. A. M., van der Heide, U. A., & Kerkhof, E. M. (2020). Radiotherapy quality assurance for mesorectum treatment planning within the multi-center phase II STAR-TReC trial: Dutch results. Radiation Oncology, 15(1), 1–10. https://doi.org/10.1186/s13014-020-01487-6
Chicago
van den Ende, Roy P. J., Femke P. Peters, Ernst Harderwijk, Heidi Rütten, Liza Bouwmans, Maaike Berbee, Richard A. M. Canters, et al. 2020. “Radiotherapy Quality Assurance for Mesorectum Treatment Planning within the Multi-Center Phase II STAR-TReC Trial: Dutch Results.” Radiation Oncology 15 (1): 1–10. doi:10.1186/s13014-020-01487-6.